To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number of people who have (a) died and (b) suffered serious illness as a result of vaccine-induced immune thrombotic thrombocytopenia after receiving the Oxford-AstraZeneca vaccine against covid-19; and whether he is taking steps to inform victims and their relatives of the provisions of the Vaccine Damage Payments Act 1979.
The Medicines and Healthcare products Regulatory Agency (MHRA) publishes weekly data on the number of reports of suspected thrombosis with thrombocytopenia syndrome. As of 24 November 2021, the MHRA had received Yellow Card reports of 427 suspected cases of major thromboembolic events with concurrent thrombocytopenia in the United Kingdom of which 74 were fatal. This follows the administration of 50 million doses of the AstraZeneca COVID-19 vaccine in the UK, including 24.9 million first and 24.1 million second doses.
The Vaccine Damage Payment Scheme covers 18 diseases, including COVID-19 and those who are concerned harm may have been caused as a result of vaccination may apply to the Scheme.